Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIBECA
2024-516237-12-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cryoglobulinaemia comparing Belimumab arm with Placebo arm (2 arms). Primary endpoint: Complete clinical response rate of vasculitis symptoms at week 25 with oral corticosteroid withdrawal at week 12. Planned start Nov 2024; status: authorised.
02
Drugs
belimumab
03
Conditions
cryoglobulinaemia
Beyond the preview
Go deeper on 2024-516237-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516237-12-00.